Stay updated with breaking news from B Cell. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Younger patients with specific genetic subtypes of non-GCB DLBCL, called MCD and N1, had an exceptional response to the treatment combination.
New research presented this week at ACR Convergence, the American College of Rheumatology's annual meeting, shows immunocompromised patients using rituximab (a drug used to treat diseases like rheumatoid arthritis) were able to produce antibodies against COVID-19 (seroconvert) after receiving a third COVID-19 vaccine dose, even if there was no development of the antibody after the first two doses of the vaccine.
.jpg)
A new study posted to the medRxiv* preprint server studies the neutralizing antibody response in cancer patients diagnosed with chronic lymphocytic leukemia (CLL), lung cancer, breast cancer, and various non-Hodgkin’s lymphomas (NHL), post-reception of two doses of messenger RNA (mRNA) vaccines.
News-Medical speaks to Professor Tomohiro Kurosaki about how he has developed a new vaccine approach that could prevent future pandemics.
Researchers opted to use single-cell RNA-seq to observe single cells in detail as they encounter a specific antigen.